From Market Studies to 'Value' Messaging, California Stem Cell/Gene Therapy Agency Bets Big on Affordability Plan

Far-reaching effort to ensure that revolutionary treatments reach all patients

May 01, 2025

∙ Paid

One of a number of presentation slides offered by CIRM, which consulted with BlueRidge Life Sciences on CIRM’s new affordability plan.

California is set to make a $295 million bet that it can turn stem cell and gene therapy research into treatments that are not only revolutionary but affordable.

The bet comes in the form of a new plan for commercializat…

Keep reading with a 7-day free trial

Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.